(b) Mean CsA dose per day.

	Randomization population1		On-treatment population2
	MMF group3	Control group4	Group I5	Group II6
M30	129 ± 37 mg	190 ± 50 mg	137 ± 48 mg	191 ± 30 mg
M48	134 ± 47 mg	180 ± 54 mg	134 ± 41 mg	205 ± 60 mg
M60	126 ± 44 mg	163 ± 43 mg	128 ± 37 mg	173 ± 63 mg

¹Patients randomized to receive either MMF or CsA treatment in the initial study phase.

²Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not).

³Patients who received 2 g MMF per day and 50% of the initial CsA dose.

⁴Patients who received the usual CsA dose.

⁵Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase.

⁶Patients without a mycophenolic acid derivative at the end of the follow up phase.